Medical 21 is developing the MAVERICS graft, a small-diameter flexible tube encased in a nitinol scaffold that eliminates the need for harvesting blood vessels during heart bypass surgery. This technology addresses the challenges of pain, recovery time, and complications associated with traditional bypass procedures, allowing patients who are typically ineligible for surgery to receive treatment.
Funding
$59.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Coronary artery bypass grafting (CABG) often requires harvesting healthy blood vessels from other parts of the patient's body, such as the legs or arms, to bypass blocked arteries. This vessel harvesting process can lead to additional pain, extended recovery times, increased risk of infection, and complications at the harvest site. Furthermore, some patients are ineligible for traditional CABG due to prior amputations, severe diabetes, or varicose veins, which limit the availability of suitable vessels for harvesting.
Solution
Medical 21 is developing the MAVERICS graft, an artificial bypass graft designed to eliminate the need for vessel harvesting during CABG procedures. The MAVERICS graft is a small-diameter, flexible tube encased in a nitinol scaffold, intended to provide a readily available conduit for bypassing blocked coronary arteries. By eliminating the need to harvest vessels, the MAVERICS graft aims to reduce patient pain, decrease procedure and recovery time, and lower the risk of infection and complications associated with traditional CABG. The MAVERICS graft may also expand the pool of eligible patients to include those who are currently not candidates for traditional bypass surgery due to the lack of suitable vessels for harvesting.
Target Audience
The primary target audience includes cardiac surgeons and hospitals seeking to improve patient outcomes and reduce the morbidity associated with traditional CABG procedures.
Features
- Small-diameter, flexible tube design for ease of implantation
- Nitinol scaffold for structural support and patency
- Designed to eliminate the need for vessel harvesting during CABG
- Intended to reduce pain, recovery time, and complications compared to traditional CABG
- May enable CABG procedures for patients currently ineligible due to lack of harvestable vessels
- Currently for investigational use only; not yet FDA approved or cleared for commercial sale